Ubiquitin-regulating effector proteins from Legionella

Minwoo Jeong*, Hayoung Jeon# & Donghyuk Shin*

Department of System Biology, College of Life Sciences and Biotechnology, Yonsei University, Seoul 03722, Korea

Ubiquitin is relatively modest in size but involves almost entire cellular signaling pathways. The primary role of ubiquitin is maintaining cellular protein homeostasis. Ubiquitination regulates the fate of target proteins using the proteasome- or autophagy-mediated degradation of ubiquitinated substrates, which can be either intracellular or foreign proteins from invading pathogens. Legionella, a gram-negative intracellular pathogen, hinders the host-ubiquitin system by translocating hundreds of effector proteins into the host cell's cytoplasm. In this review, we describe the current understanding of ubiquitin machinery from Legionella. We summarize structural and biochemical differences between the host-ubiquitin system and ubiquitin-related effectors of Legionella. Some of these effectors act much like canonical host-ubiquitin machinery, whereas others have distinctive structures and accomplish non-canonical ubiquitination via novel biochemical mechanisms. [BMB Reports 2022; 55(7): 316-322]

INTRODUCTION

Regulation of cellular activities relies on various post-translational modifications (PTM), such as phosphorylation, glycosylation, or acetylation (1-3). Unlike the aforementioned PTM that transfers chemical moieties to the targets, ubiquitination ligates ubiquitin protein to the substrates (4, 5). The covalent attachment of the C-terminal carboxyl group of ubiquitin to the amine group of lysine residues on a target protein is called monoubiquitination. Ubiquitin also forms different types of chains, called polyubiquitin, through the ubiquitination on an amino group of 7 lysine residues (K6, K11, K27, K29, K33, K48, K63) or the first methionine (M1) residue of ubiquitin. The diverse conformational complexity of polyubiquitin chains gives cells abilities to differentiate and regulate various cellular processes. M1-linked polyubiquitin chain participates in inflammation and immune response. In the NF-kappaB (NF-kB) pathway, linear ubiquitin chain assembly complex (LUBAC) modifies NEMO, a subunit of inhibitor of kB (I kB) kinase (IKK) with M1 linkage that triggers phosphorylation of IkB (6-10). K6-linked polyubiquitin participates in DNA repair events and mitochondria stability (11-13), while K11- and K48-linked polyubiquitin is related to proteasomal degradation (14-17). K27-linked polyubiquitin controls DNA damage response and innate immune response. For instance, K27-linked polyubiquitination on histone 2A caused by RNF168 is related to DNA damage response (18). K29-linked polyubiquitination is associated with the Wnt signaling pathway, which regulates embryogenesis and tumorigenesis. K29-linked polyubiquitination on Axin, a scaffold protein in the Wnt signaling, disturbs interaction with LPR5/6 and inhibits the Wnt signaling (19, 20). It is known that K33 linkage participates in the regulation of T-cell antigen receptor and AMP-activated protein kinase-related protein kinase (21, 22). Together with K11-linked chain, K48 linkage plays a crucial role in the proteasome-dependent degradation pathway and ERAD pathway. Ubiquitin receptor on proteasome recognizes homotypic K48 linkage chain on the substrates and guides the substrate to enter the proteasome (15, 23). K63 linkage participates in proteasome DNA damage repair and endosomal-lysosomal system (24, 25). Also, K63 linkage plays an essential role in immune signaling. K63 polyubiquitin chain acts as docking sites in immune pathway proteins. K63-linked polyubiquitin chain on MALT1 is related to I kB degradation and NF-kB activation (26). Moreover, K63 linkage is associated with immunomodulatory function in T cells and NLR-mediated signaling, and STING signaling in viral infections (27, 28).

The canonical ubiquitination system consists of three stages of the catalytic cascade (1, 29). The ubiquitin-activating enzyme (E1) hydrolyzes ATP and catalyzes acyl adenyllyation of the ubiquitin. The AMP-Ub intermediate forms a thioester bond with the catalytic cysteine of the E1 (1, 30). Next, Ub on the E1 is transferred to the catalytic cysteine on the ubiquitin-conjugating enzyme (E2) (31, 32). Finally, E2 works with the ubiquitin ligation enzyme (E3) to attach Ub to the substrate. E3 ligases are divided into three major classes (HECT, RING, and U-box, RBR). Each of them has a unique mechanism to transfer ubiquitin to a substrate (33, 34). Most E3 ligases make an isopeptide bond between the carboxyl terminus of the ubiquitin and the amino group of Lys on the target protein or preceding Ub (1). All E3 ligases bind to E2-Ub thioesters and catalyze the transfer of ubiquitin from E2 to the substrate lysine. In particular,
HECT (Homologous to E6-associated protein C terminus) type E3s have catalytic cysteine that accepts ubiquitin from E2 via the transthioesterification reaction (35). In contrast, RING (Really Interesting New Gene) type E3 ligases have no active site residues and mediate direct ubiquitin transfer from E2 to the substrates. RING E3 ligase contains a RING (or RING-like) domain responsible for binding to E2 and stimulating the ubiquitination transfer (36). The RING domain generally adopts a cross-brace structure with two structural Zn$^{2+}$ ions. A related domain, known as a U-box, is similar in function and structural fold but has a hydrophobic core instead of the structural metal ion (37). The RBR (RING-between-RING) has two RING domains but combines roles of both RING and HECT E3 ligase (38, 39). One of the RING domains of RBR binds to E2 like the canonical RING domain, while the other RING domain accepts ubiquitin in a similar way to the HECT E3 ligases. Similar to other PTM, ubiquitination is also a reversible process, and the ubiquitin on the target proteins is recycled by deubiquitinase (DUB), which cleaves the isopeptide bond between ubiquitin and the substrate. About 100 types of DUBs have been identified in humans, and they are classified into seven superfamilies. Six of them (USP, OTU, MJD, UCH, MINDY, and ZUFSP) are cysteine proteases, whereas JAMM belongs to a zinc-containing metalloprotease (40, 41).

*Legionella pneumophila* is a gram-negative pathogenic bacteria causing Legionnaires’ disease (42). *Legionella* uses more than 300 effector proteins during the infection. These effectors disrupt the host cellular processes and create an ideal environment for bacterial survival and replication inside the host cell (43). Many of these effectors target the host ubiquitin system. For instance, RavZ (Region allowing vacuole colocalization Z) hydrolyzes carboxyl-terminal glycine of Atg8 and blocks the host autophagy (44). The SdeC (Substrates of Icm/Dot transporter E) family effector mediates non-canonical phosphoribosyl ubiquitation, which is required for ER- or Golgi compartment disruption (45, 46). In addition, RavD (Region allowing vacuole colocalization D) effector cleaves the M1 polyubiquitin chain to block the host NF-$\kappa$B signaling pathway (47). These results show that Legionella has developed various machinery that alters host ubiquitin signaling in canonical or non-canonical ways. Structural and biochemical studies on these effectors revealed that some effectors mimic the host proteins to participate in the host cellular processes, whereas others have completely different structures and mediate novel biochemical reactions. This review highlights structural and biochemical differences of Legionella proteins involved in the host ubiquitin system.

**CANONICAL UBIQUITIN SYSTEM-RELATED LEGIONELLA EFFECTORS**

**LubX (Legionella U-box E3-ligase)**

Some effectors have been demonstrated to interact directly with the host ubiquitination machinery using the U-box or F-box domain. Both LegU1 and LegAU13 are F-box proteins and integrate into mammalian SCF complexes (Skp, Culin, F-box containing complex), and the LegU1 SCF complexes ubiquitinate host chaperone protein BAT3 (48, 49). Another Legionella effector, LubX (Lpg2830), is a U-box E3 ligase (50). Like the eukaryotic U-box, LubX has E2 specificity and interacts with either E2s (UBE2D1, UBE2D3, UBE2D2, UBE2D4, UBE2E2, UBE2E3, UBE2W1, and UBE2L6) (51, 52). Intriguingly, LubX has two U-box motifs (U-box-1 and U-box-2). However, the LubX U-box-2 domain alone shows no E3 activity, whereas LubX U-box-1 is sufficient for interacting with E2s and catalyzes polyubiquitination. Structural analysis of LubX U-box-1 in a complex with human UBE2D2 reveals that most of the LubX U-box-1:UBE2D2 binding interface residues are not conserved in LubX U-box-2 (53). The overall structure of LubX:UBE2D2 is similar to the human UBE4B U-box:UBE2D3 complex (Fig. 1).
Ubiquitin-regulating effector proteins from Legionella
Minwoo Jeong, et al.

1A) (54). However, residues at the binding interface differ from each other. Although both LubX U-box-1 and human UBE4B bind to the Aa-Pro-Ser hydrophobic patch on E2s, LubX U-box-1 makes additional hydroxyl bond networks between Ile39-Arg5, Lys68-Ser91, and Arg75-Glu92. Importantly, these residues are not conserved in LubX U-Box-2. These structural analyses indicate that Legionella U-box distinguishes E2s through the sequence diversity on the U-box:E2 interface, just as the other U-box does. Functional roles of LubX E3 ligase is also reported. As a metaeffectector, LubX target another substrate of the Dot/Icm system (52). LubX promotes human Cdc2-like kinase1 (Clk1) degradation. Clk1 plays an important role in the modulation of host cellular processes. As a result, Clk1 contributes to maximum Legionella growth in mouse macrophages. In addition, LubX mediates proteasomal degradation of SidH (another effector protein of Dot/Icm system) (51, 52).

**Legionella OTU-like deubiquitinases (Lot-DUBs)**

Not only E3 ligases but also deubiquitinases are found in *Legionella*. Among seven DUB superfamilies, the OTU (Ovarian Tumour deubiquitinase) family explicitly shows linkage specificity toward polyubiquitin chains (55). For example, human OTUB1 preferentially cleaves the Lys48-linked chain, and human tumor deubiquitinase) family explicitly shows linkage specificity toward polyubiquitin chains (55). For example, human OTUB1 preferentially cleaves the Lys48-linked chain, and human OTUBLIN cleaves the M1-linked chain (56-58). Interestingly, *Legionella* has several OTU-like DUBs (Legionella OTU-like DUBs, LotA, LotB, and LotC), and they also show different linkage specificities (59). Intriguingly, LotA has two OTU domains (LotA OTU1, LotA OTU2), whereas LotB and LotC have a single OTU domain (60, 61). The LotA OTU1 domain preferentially cleaves K6-linked di ubiquitin, but the LotA OTU2 domain cleaves longer K48- and K63-linked chains (60). LotB cleaves K63-linked di- and polyubiquitin chains, and LotC cleaves K6-, K11-, K23-, K48-, and K63-linked di ubiquitin (Di-Ub) chains (62-64).

The crystal structure of LotA OTU2, LotB, and LotC revealed that all three Lots consist of a catalytic domain (green) and an extended helical lobe (EHL) (yellow) (Fig. 1B). Because the EHL is not found in any other OTU family, EHL defines *Legionella* OTU DUBs as a unique OTU subfamily. Notably, the EHL domain provides a ubiquitin-binding site that interacts with ubiquitin through hydrophobic or electrostatic interactions in *Legionella* (60, 61, 63). LotA OTU2 binds to positively charged ubiquitin residues (R42, R72, R74) through the acidic patch (D407, D410, D412) on the EHL. Indeed, the D410R mutant decreases the catalytic activity against K48- and K63-linked polyubiquitin. In addition, LotA OTU2 EHL binds to the hydrophobic 144 patch of distal ubiquitin through its hydrophobic surface around V398. LotB EHL also plays an important role in ubiquitin-binding. F143 and M144 of LotB EHL bind to the hydrophobic patch around F43 and A46 on the ubiquitin (60, 63). The EHL on LotC also provides a binding site for ubiquitin, and mutations on EHL (Y119R or Y149R) decrease the K48-linked ubiquitin cleavage activity of LotC. Therefore, the EHL domain, which is not found in the eukaryotic OTU-DUB, seems to be a critical determinant for providing the linkage specificity of Legionella OTUs (60). Though the exact functional role of all three Lots during infection is not clear, proteomics studies reveal how Lots regulates these substrates (60).

**RavD (region allowing vacuole colocalization D)**

RavD is another *Legionella* DUB that explicitly cleaves the M1-linked linear ubiquitin chain. The structure of RavD in complex with a linear di-ubiquitin chain revealed that di-ubiquitin uses the same binding interface as it binds to human M1-specific deubiquitinase OTUBLIN (Fig. 1C) (57). Given the crystal structure of RavD, it was suggested that RavD does not use a substrate-assisted catalytic activation mechanism as OTUBLIN does. However, recent studies indicate that both RavD and OTUBLIN use a common mechanism for recognizing the M1-ubiquitin chain (65, 66). Molecular dynamic simulations on the microsecond scale of RavD in complex with di-ubiquitin suggest that ubiquitin at the S1’ site has flexibility and that the binding affinity is substantially weaker than at the S1 site. These results indicate that RavD also uses substrate-assisted catalysis as OTUBLIN does (47, 66).

**NON-CANONICAL UBQUITINATION-RELATED LEGIONELLA EFFECTORS**

**Phosphoribosyl ubiquination**

Sid family effectors (Substrates of Icm/Dot transporter E, SidEs) are multi-domain proteins. They consist of a deubiquitinase domain, PDE (phosphodiesterase) domain, mART (mono ADP ribosyl transferase) domain, and a coiled-coil domain. When SidEs are translocated in the host cell, they catalyze a unique ubiquitination process on host proteins, called phosphoribosyl ubiquitination (Fig. 2A) (67). The mART domain on SidEs transfers the ADP-ribose moiety from NAD+ (nicotinamide adenine dinucleotide) to Arg42 of ubiquitin and generates ADP-ribosylated ubiquitin (ADPR-Ub). The ADPR-Ub is then processed by the PDE domain (68). PDE releases the AMP moiety from ADPR-Ub and produces phosphoribosyl ubiquitin (PR-Ub) in the absence of a substrate. When there is a substrate during the ADPR-Ub processing, PR-Ub is transferred to a serine residue on substrate proteins. Like canonical ubiquitination, deubiquitinases specific to PR-Ub are also present (46, 69). DupA and DupB (Deubiquitinase for PR-ubiquitination A and B) are also Legionella effectors, and each has a phosphodiesterase domain. DupA/VB cleaves and releases PR-Ub from serine residues in the substrate. *Legionella* also regulates SidEs by directly inhibiting the mART domain using the glutamylation by SidJ or SdjA (70-75). Most of the PR-ubiquitination machinery’s structures are determined (46, 67, 68, 70, 71, 73, 76-79), and structures of both mART and PDE domains of SidEs differ from functionally similar enzymes found in other organisms. In humans, ADP-ribosylation is catalyzed by the poly-ADP-ribose polymerase (PARP) family (80). A comparison of SidE mART with...
Fig. 2. The overall scheme of phosphoribosyl ubiquitination and structures of key effectors. (A) Phosphoribosyl ubiquitination pathway. SidE family effectors (SidEs) consist of a PDE (phosphodiesterase) domain and a mART (mono ADP ribosyl transferase) domain, which can cause phosphoribosyl ubiquitination. The mART domain on SidEs transfers the ADP-ribose moiety from NAD+ (nicotinamide adenine dinucleotide) to Arg42 of ubiquitin and generates ADP-ribosylated ubiquitin (ADPR-Ub). The PDE domain then processes the ADPR-Ub. PDE releases AMP moiety from ADPR-Ub and generates phosphoribosyl ubiquitin (PR-Ub). PR-Ub is transferred to a serine residue on substrate proteins. DupA and DupB are phosphodiesterases that cleave and release PR-Ub from serine residues in the substrate. (B) Structural comparison between the SidE mART domain (PDB ID: 5ZQ5), PARP1 ART (PDB ID: 4DQY), and PARP3 ART domain (PDB ID: 4GV4). The structure of the SidE PDE domain (PDB ID: 5ZQ5) and human Phosphodiesterase 4B (PDB ID: 50H1) are compared. (C) Structural comparison of DupA (PDB: 6RYB), DupB (PDB: 6B7M), and SidE PDE (PDB ID: 5ZQ5).

human PARP1 and PARP3 clearly shows the overall structural differences (Fig. 2B). SidE mART is also different from the mART of other organisms (HopU1 from Pseudomonas syringae, XopAI from Xanthomonas axonopodis) and shows unique conformations (77). The PDE domain of SidEs also shows unique structural features. Most of the phosphodiesterases found in humans have a cap lobe sitting on the top of the catalytic core. In contrast, the SidE PDE cap lobe is not located next to the catalytic core (Fig. 2C). Interestingly, both DupA and DupB share a structure similar to that of the SidE PDE domain and use identical catalytic sites while they mediate opposite reactions (PR-ubiquitin transfer and PR-ubiquitin cleavage) (Fig. 2D). It is shown that DupA/B have a strong affinity to Ub, ADPR-Ub, and PR-ubiquitinated peptides. In contrast, the SdeA PDE domain has a weak affinity and doesn’t integrate with PR-ubiquitinated peptides. High affinity to the PR-ubiquitinated substrate results in PR-deubiquitinase activity of DupA/B (46).

Fig. 3. The overall scheme of transglutaminase-mediated ubiquitination of Ube2N and structural comparison of MavC and MvcA. (A) Transglutaminase-induced Ube2N ubiquitination mechanism. MavC (Prg2147) binds to activated Ube2N-Ub. Intramolecular transglutaminase generates an isopeptide bond between the Gln40 of ubiquitin and the Lys92 of Ube2N. MvcA (Prg2148) specifically cleaves Ub from the Ube2N-Ub produced by MavC. (B) Structural comparison of MavC (PDB ID: 5TSC), MvcA (PDB ID: 6K11), and cif (PDB ID: 4F8C). Catalytic cysteines are color-coded in red.

Transglutaminase induced ubiquitination MavC (More regions allowing vacuole colocalization C, Lpg2147) and MvcA (MavC paralog A, Lpg2148) were initially discovered as ubiquitin Gln40 deamidase (81). Structural and biochemical studies reveal that MavC binds to an activated Ube2N-Ub conjugate and catalyzes an intramolecular transglutaminase reaction to produce a covalent bond between Gln40 of Ub and
Lys92 of Ube2N (82, 83). In contrast,MvcA cleaves ubiquitin from Ube2N and reverses the MavC-mediated Ube2N ubiquitination (Fig. 3A) (84). Another *Legionella* effector, Lpg2149, binds to MavC and MvcA and blocks their function (81, 85). Structural comparison of MavC and MvcA to the Cif effector revealed that both MavC and MvcA have a large insertion domain on the top of the catalytic pocket (Fig. 3C) (81). An interesting point is that MavC and MvcA share a 50% sequence identity, use the same catalytic triad, and have similar structural folds while performing opposite reactions. Structural studies reveal that the substrate-recognition region on the MvCa defines its role as a deubiquitinase (84).

**CONCLUSION**

This mini-review summarized current understandings of the *Legionella* effector proteins that regulate host ubiquitin signaling. *Legionella* hijacks host ubiquitination systems by using effectors similar to canonical ubiquitin ubiquitination machinery or alters ubiquitination systems by introducing non-canonical ubiquitination systems, such as phosphoribosyl ubiquitination and transglutaminase-induced ubiquitination. Structural analysis of both canonical and non-canonical ubiquitin effectors revealed that these effectors have structures that distinguish them from host ubiquitination systems. *Legionella* OTU-like deubiquitinases (LotA/B/C), mART, PDE, and MavC MvcA, have additional structural motifs or insertion regions that participate in the catalytic reaction or ubiquitin recognition. More importantly, it seems to be a general phenomenon in *Legionella* that a pair of similar effectors performs opposite reactions. SidE PDE transfers PR-ubiquitin, while DupA/B PDE removes PR-ubiquitin. MvC induces Ub2N ubiquitination, whereas MvcA reverses this reaction. They use identical catalytic residues but have different binding affinity or specificity for the substrates to define their roles.

Interestingly, the non-canonical ubiquitination mechanisms—phosphoribosyl ubiquitination and transglutaminase-induced ubiquitination—are found only in *Legionella*. Because *Legionella* is not the only pathogen that translocates effectors to the host cells, it might be possible to discover similar ubiquitin-regulating machinery from other pathogens. Further research is awaited to see whether the novel non-canonical ubiquitination system exists in another organism and to understand how these unique effectors are developed in *Legionella*. Yet, other human pathogens do not have such systems.

**ACKNOWLEDGEMENTS**

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2021R1C1C100396112 and 2018R1A6A1A0302560722) and the Yonsei University Research Fund of 2021 (2021-22-0005).

**CONFLICTS OF INTEREST**

The authors have no conflicting interests.

**REFERENCES**

1. Hershko A and Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67, 425-479
2. Mann M and Jensen ON (2003) Proteomic analysis of post-translational modifications. Nat Biotechnol 21, 255-261
3. Olsen JV and Mann M (2013) Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol Cell Proteomics 12, 3444-3452
4. Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Nalli HD and Boyse EA (1975) Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci U S A 72, 11-15
5. Yau R and Rape M (2016) The increasing complexity of the ubiquitin code. Nat Cell Biol 18, 579-586
6. Gerlach B, Cordier SM, Schmukle AC et al (2011) Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471, 591-596
7. Ikeda F, Rahighi S, Wakisaka S and Dikic I (2011) Selective binding of linear ubiquitin chains to NEMO in NF-kappaB activation. Adv Exp Med Biol 691, 107-114
8. Kirisako T, Kamei K, Murata S et al (2006) A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 25, 4877-4887
9. Tokunaga F, Sakata S, Saeki Y et al (2009) Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 11, 123-132
10. Walczak H, Iwai K and Dikic I (2012) Generation and physiological roles of linear ubiquitin chains. BMC Biol 10, 23
11. Morris JR and Solomon E (2004) BRCA1 : BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet 13, 807-817
12. Nishikawa H, Ooka S, Sato K et al (2004) Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem 279, 3916-3924
13. Orudreu A, Sarraf SA, Duda DM et al (2014) Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol Cell 56, 360-375
14. Braten O, Livneh I, Ziv T et al (2016) Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. Proc Natl Acad Sci U S A 113, E4639-E4647
15. Chau V, Tobias JW, Bachmair A et al (1989) A multibiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576-1583
16. Gregori L, Pooch MS, Cousins G and Chau V (1990) A uniform isopeptide-linked multibiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis. J Biol Chem 265, 8354-8357
17. Shabek N, Herman-Bachinsky Y, Buchsbaum S et al (2012)
The size of the proteasomal substrate determines whether its degradation will be mediated by mono- or polyubiquity-
lization. Mol Cell 48, 87-97
18. Gatti M, Pinato S, Maiolica A et al (2015) RNF168 pro-
motes noncanonical K27 ubiquitination to signal DNA dam-
age. Cell Rep 10, 226-238
19. Clevers H and Nusse R (2012) Wnt/beta-catenin signaling
and disease. Cell 149, 1192-1205
20. Fei C, Li Z, Li C et al (2013) Smurf1-mediated Lys29-linked
nonproteolytic polyubiquitination of axin negatively regu-
lates Wnt/beta-catenin signaling. Mol Cell Biol 33, 4095-
4105
21. Al-Hakim AK, Zagorska A, Chapman L, Desaik M, Pegg M
and Alessi DR (2008) Control of AMPK-related kinases by
USP15 and atypical Lys29/Lys33-linked polyubiquitin
chains. Biochem J 411, 249-260
22. Huang H, Leon MS, Liao L et al (2010) K33-linked poly-
ubiquitination of T cell receptor-zeta regulates proteolysis-
dependent T cell signaling. Immunity 33, 60-70
23. Thower JS, Hoffman L, Rechsteiner M and Pickart CM
(2000) Recognition of the polyubiquitin proteolytic signal.
EMBO J 19, 94-102
24. Duncan LM, Piper S, Dodd RB et al (2006) Lysine-63-linked
ubiquitination is required for endolysosomal degradation
of class I molecules. EMBO J 25, 1635-1645
25. Hofmann RM and Pickart CM (1999) Noncanonical MMS2-
coded ubiquitin-conjugating enzymes in assembly of
novel polyubiquitin chains for DNA repair. Cell 96, 645-
653
26. Ockinghaus A, Wegener E, Welteke V et al (2007) Multi-
ubiquitination triggers NF-kappaB signaling upon T-cell
activation. EMBO J 26, 4634-4645
27. Ni X, Kou W, Gu J et al (2019) TRAF6 directs FOXP3
localization and facilitates regulatory T-cell function through
K63-linked ubiquitination. EMBO J 38, e99766
28. Wang J, Yang S, Liu L, Wang H and Yang B (2017)
HTLV-1 Tax impairs K63-linked ubiquitination of STING
to evade host innate immunity. Virus Res 232, 13-21
29. Husnjak K and Dikic I (2012) Ubiquitin-binding proteins:
decoders of ubiquitin-mediated cellular functions. Annu
Rev Biochem 81, 291-322
30. Schulman BA and Harper JW (2009) Ubiquitin-like pro-
tein activation by E1 enzymes: the apex for downstream
signalling pathways. Nat Rev Mol Cell Biol 10, 319-331
31. Olsen SK and Lima CD (2013) Structure of a ubiquitin
E1-E2 complex: insights to E1-E2 thioester transfer. Mol
Cell 49, 884-896
32. Ye Y and Rape M (2009) Building ubiquitin chains: E2
enzymes at work. Nat Rev Mol Cell Biol 10, 755-764
33. Buettow L and Huang DT (2016) Structural insights into
the catalysis and regulation of E3 ubiquitin ligases. Nat Rev
Mol Cell Biol 17, 626-642
34. Deshaies RJ and Joazeiro CA (2009) RING domain E3
ubiquitin ligases. Annu Rev Biochem 78, 399-434
35. Berndsen CE and Wobbergen C (2014) New insights into
ubiquitin E3 ligase mechanism. Nat Struct Mol Biol 21,
301-307
36. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S and
Weissman AM (1999) RING fingers mediate ubiquitin-
conjugating enzyme (E2)-dependent ubiquitination. Proc
Natl Acad Sci U S A 96, 11364-11369
37. Ohl MD, Vander Kooi CW, Rosenberg JA, Chazin WJ and
Gould KL (2003) Structural insights into the U-box, a
domain associated with multi-ubiquitination. Nat Struct
Biol 10, 250-255
38. Marin I and Ferrus A (2002) Comparative genomics of the
RBR family, including the Parkinson’s disease-related gene
parkin and the genes of the ariadne subfamily. Mol Biol
Evol 19, 2039-2050
39. Spratt DE, Walden H and Shaw GS (2014) RBR E3 ubi-
quitin ligases: new structures, new insights, new questions.
Biochem J 458, 421-437
40. Kwasna D, Abdul Rehman SA, Natarajan J et al (2018)
Discovery and characterization of ZUFSP/ZUP1, a distinct
deu ubiquitin class important for genome stability. Mol Cell
70, 150-164 e156
41. Reyes-Turcu FE, Ventii KH and Wilkinson KD (2009) Re-
gulation and cellular roles of ubiquitin-specific deubiquiti-
nating enzymes. Annu Rev Biochem 78, 363-397
42. Field RS, Benson RF and Besser RE (2002) Legionella
and Legionnaires’ disease: 25 years of investigation. Clin Microbiol
Rev 15, 506-526
43. Ashida H, Kim M and Sasaki C (2014) Exploitation of
the host ubiquitin system by human bacterial pathogens.
Nat Rev Microbiol 12, 399-413
44. Choy A, Dancourt J, Mugo B et al (2012) The Legionella
effector RavZ inhibits host autophagy through irreversible
Atg8 deconjugation. Science 338, 1072-1076
45. Liu Y, Mukherjee R, Bonn F et al (2021) Serine-ubiquiti-
tination regulates Golgi morphology and the secretory
pathway upon Legionella infection. Cell Death Differ 28,
2957-2969
46. Shin D, Mukherjee R, Liu Y et al (2020) Regulation of
phosphoribosyl-linked serine ubiquitination by deubiquiti-
nases DupA and DupB. Mol Cell 77, 164-179 e166
47. Wan M, Wang X, Huang C et al (2019) A bacterial effec-
tor deubiquitinasen specifically hydrolyzes linear ubiquitin
cchains to inhibit host inflammatory signalling. Nat Microbiol
4, 1282-1293
48. Ensminger AW and Isberg RR (2010) E3 ubiquitin ligase
activity and targeting of BAT3 by multiple Legionella pneu-
mophila translocated substrates. Infect Immun 78, 3905-
3919
49. Price CT, Al-Khodor S, Al-Quadan T et al (2009) Molecular
mimicry by an F-box effector of Legionella pneumophila
hijacks a conserved polyubiquitination machinery within
macrophages and protozoa. PLoS Pathog 5, e1000704
50. Miyamoto K and Saito K (2018) Concise machinery for
Ubiquitin-regulating effector proteins from Legionella
Minwoo Jeong, et al.
Molecular basis for the association of human E4B U box ubiquitin ligase with E2-conjugating enzymes UbCh5c and UbC4. Structure 18, 955-965.

55. Mevissen TE and Komander D (2017) Mechanisms of ubiquitinase specificity and regulation. Annu Rev Biochem 86, 159-192.

56. Edelmann MJ, Iphofer A, Akutsu M et al (2009) Structural basis and specificity of human otubain 1-mediated deubiquitination. Biochem J 418, 379-390.

57. Keusekotten K, Elliott PR, Glockner L et al (2013) OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 153, 1312-1326.

58. Mevissen TE, Hospenthal MK, Geurink PP et al (2013) OTU deubiquinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell 154, 169-184.

59. Kitao T, Nagai H and Kubori T (2020) Divergence of Legionella effectors reversing conventional and unconventional ubiquitination. Front Cell Infect Microbiol 10, 448.

60. Shin D, Bhattacharya A, Cheng YL et al (2020) Bacterial ubiquitin-regulating effector proteins from Legionella. Minwoo Jeong, et al. 322 BMB Reports http://bmbreports.org